LYS006

selective oral LTA4H metalloenzyme inhibitor

in multiple inflamm. Ph. II incl. colitis + NASH

1800 cmpd fragment screen + frag. merging

J. Med. Chem., Feb. 16, 2021

Novartis, Basel, CH

2. The Novartis LTA4H metalloenzyme inhibitor, LYS006, is a selective oral agent in multiple Ph. II studies to treat inflammatory diseases including ulcerative colitis and NASH. The starting points…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.